A retrospective analysis of radiation therapy for the treatment of feline vaccine‐associated sarcoma* |
| |
Authors: | C Eckstein F Guscetti M Roos J Martín de las Mulas B Kaser‐Hotz C Rohrer Bley |
| |
Institution: | 1. Diagnostic Imaging and Radio‐Oncology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland;2. Institute of Veterinary Pathology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland;3. Biostatistics Unit, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland;4. Department of Comparative Pathology, Veterinary School, University of Córdoba, Campus de Rabanales, Córdoba, Spain |
| |
Abstract: | We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine‐associated sarcoma given postsurgical curative (n = 46, most with clean margins) or coarse fractionated radiotherapy (n = 27, most with either macroscopic disease or dirty margins). The former animals displayed a median survival of 43 months and a median progression free interval (PFI) of 37 months, the latter reached a median survival of 24 months and a median PFI of 10 months. In cats undergoing coarse fractionated therapy, factors predictive of a better outcome included lack of visible mass (n = 10) as opposed to macroscopic disease (n = 17, survival: 30 versus 7 months, P = 0.025; PFI: 20 versus 4 months, P = 0.01), adjuvant chemotherapy for gross disease (n = 5/17, survival: 29 versus 5 months, P = 0.04) and a smaller number of surgeries preceding radiation therapy (coeff = 0.41, P = 0.03). The Ki67 index was not predictive for survival. We concluded that postsurgical curative and coarse fractionated radiotherapy are effective legitimate options for managing vaccine‐associated sarcomas. |
| |
Keywords: | coarse fractionated radiotherapy curative radiotherapy feline vaccine‐associated sarcoma Ki67 index |
|
|